Drug Landscape ›
COLISTIN SULFATE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 267
Most-reported reactions
Renal Failure Acute — 45 reports (16.85%) Drug Ineffective — 38 reports (14.23%) Infection — 34 reports (12.73%) Pyrexia — 25 reports (9.36%) Sepsis — 25 reports (9.36%) Blood Creatinine Increased — 21 reports (7.87%) Drug Interaction — 21 reports (7.87%) Condition Aggravated — 20 reports (7.49%) Cystic Fibrosis — 19 reports (7.12%) Septic Shock — 19 reports (7.12%)
Source database →
COLISTIN SULFATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is COLISTIN SULFATE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for COLISTIN SULFATE in United States?
Marketing authorisation holder not available in our data.